Hims & Hers Health Past Earnings Performance
Past criteria checks 0/6
Hims & Hers Health has been growing earnings at an average annual rate of 2.8%, while the Healthcare industry saw earnings growing at 7.1% annually. Revenues have been growing at an average rate of 51.4% per year.
Key information
2.8%
Earnings growth rate
41.1%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | 51.4% |
| Return on equity | -6.8% |
| Net Margin | -2.7% |
| Next Earnings Update | 06 May 2024 |
Recent past performance updates
Recent updates
Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation
Apr 05Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock
Mar 21Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
Mar 12Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%
Feb 28
Hims & Hers: Turning The Profitability Corner And Returning 28%
Feb 25Hims & Hers Health: No Clear Moat Besides First Mover Advantage
Jan 23Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple
Jan 10Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)
Jan 07Hims & Hers Health Q3: The Cheapest Growth Stock Around
Dec 14Hims & Hers Health: What Would The Author Of 100 Baggers Say?
Nov 30Hims & Hers: The Most Undervalued Small Cap Stock I See
Nov 08Hims & Hers: A Promising Company With Resolvable Challenges
Nov 02Hims & Hers: Specialization Is The Secret To Great Growth
Oct 25Hims & Hers Health: Can't Get Much Better
Sep 25The Market Is Wrong On Hims & Hers Health
Sep 18Hims & Hers: The Current Weakness Creates A Buying Opportunity
Aug 15Hims & Hers Health: Giving Investors Another Bite At The Apple
Aug 01Hims & Hers Health, Inc.'s (NYSE:HIMS) Price In Tune With Revenues
Jul 21Hims & Hers Health: Expect Strong EBITDA Growth As Revenue Growth Remains Strong
Jul 13Hims & Hers Health: Double-Edged Sword
Jul 02Hims & Hers: More Transparency Could Help The Stock
Jun 09Hims & Hers Health (NYSE:HIMS) Is In A Strong Position To Grow Its Business
Apr 19Are Investors Undervaluing Hims & Hers Health, Inc. (NYSE:HIMS) By 41%?
Mar 30Him & Hers Health Q4 2022 Earnings Preview
Feb 24Hims & Hers spikes as Jefferies upgrades ahead of 2023 guidance
Feb 09Hims & Hers: Profitability Pulled Forward
Jan 25Hims & Hers Health: Buy Into The Strong Growth Momentum
Jan 18Devon Energy And Hims & Hers Health - Raul Shah's Hot Take
Jan 05Hims & Hers Health: The Ultimate Pick For 2023
Dec 23Hims & Hers Health: The Unicorn (Former) SPAC For 2023
Dec 17Hims & Hers Health Seems Like A Great Pick For 2023
Dec 10Party Time: Brokers Just Made Major Increases To Their Hims & Hers Health, Inc. (NYSE:HIMS) Earnings Forecasts
Nov 12Revenue & Expenses BreakdownBeta
How Hims & Hers Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 872 | -24 | 693 | 48 |
| 30 Sep 23 | 793 | -36 | 639 | 43 |
| 30 Jun 23 | 711 | -47 | 581 | 39 |
| 31 Mar 23 | 616 | -59 | 514 | 34 |
| 31 Dec 22 | 527 | -66 | 446 | 29 |
| 30 Sep 22 | 444 | -86 | 381 | 26 |
| 30 Jun 22 | 374 | -83 | 324 | 35 |
| 31 Mar 22 | 321 | -73 | 281 | 28 |
| 31 Dec 21 | 272 | -108 | 289 | 22 |
| 30 Sep 21 | 229 | -82 | 250 | 17 |
| 30 Jun 21 | 196 | -72 | 217 | 0 |
| 31 Mar 21 | 171 | -63 | 186 | 0 |
| 31 Dec 20 | 149 | -18 | 113 | 11 |
| 30 Sep 20 | 132 | -25 | 117 | 0 |
| 30 Jun 20 | 112 | -38 | 114 | 0 |
| 31 Mar 20 | 95 | -58 | 117 | 0 |
| 31 Dec 19 | 83 | -72 | 119 | 0 |
| 31 Dec 18 | 27 | -75 | 84 | 0 |
Quality Earnings: HIMS is currently unprofitable.
Growing Profit Margin: HIMS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HIMS is unprofitable, but has reduced losses over the past 5 years at a rate of 2.8% per year.
Accelerating Growth: Unable to compare HIMS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HIMS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (7.3%).
Return on Equity
High ROE: HIMS has a negative Return on Equity (-6.84%), as it is currently unprofitable.